Statin use vs. average non-HDL cholesterol levels in Ghana

Ghana: Statin use vs. average non-HDL cholesterol levels was 3.3 in 2018. ▲ Rising

Latest (2018)
3.3
Change on year
unchanged
World rank
95th
of 191 countries
All-time high
3.3
in 2016
All-time low
2.8
in 1980
Years of data
39
1980–2018

Statin use vs. average non-HDL cholesterol levels in Ghana, 1980–2018

01231980199920181980: 2.81981: 2.81982: 2.81983: 2.81984: 2.81985: 2.81986: 2.81987: 2.81988: 2.81989: 2.81990: 2.81991: 2.81992: 2.81993: 2.81994: 2.81995: 2.91996: 2.91997: 2.91998: 2.91999: 2.92000: 2.92001: 2.92002: 2.92003: 32004: 32005: 32006: 32007: 32008: 3.12009: 3.12010: 3.12011: 3.22012: 3.22013: 3.22014: 3.22015: 3.22016: 3.32017: 3.32018: 3.3

Source: World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.

Analysis

The most recent figure for statin use vs. average non-hdl cholesterol levels in Ghana is 3.3, measured in 2018. That is the highest value across all 39 years on record.

The figure is up 6.5% over ten years.

Over the whole period, statin use vs. average non-hdl cholesterol levels in Ghana peaked at 3.3 in 2016 and was at its lowest, 2.8, in 1980.

Ghana ranks 95th of 191 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 39 years of available data.

Averages by decade

DecadeAverage LowestHighest Years
1980s 2.8 2.8 2.8 10
1990s 2.85 2.8 2.9 10
2000s 2.99 2.9 3.1 10
2010s 3.22 3.1 3.3 9

Countries ranked near Ghana

  1. 95 Algeria 3.3 compare
  2. 95 Azerbaijan 3.3 compare
  3. 95 Bahrain 3.3 compare
  4. 95 Barbados 3.3 compare
  5. 95 Bolivia 3.3 compare
  6. 95 Bosnia and Herzegovina 3.3 compare
  7. 95 Cambodia 3.3 compare
  8. 95 China 3.3 compare
  9. 95 Cuba 3.3 compare
  10. 95 Egypt 3.3 compare
  11. 95 Kiribati 3.3 compare
  12. 95 Laos 3.3 compare
  13. 95 Marshall Islands 3.3 compare
  14. 95 Netherlands 3.3 compare
  15. 95 Spain 3.3 compare
  16. 95 Sri Lanka 3.3 compare
  17. 95 Suriname 3.3 compare
  18. 95 Turkey 3.3 compare
  19. 95 Turkmenistan 3.3 compare
  20. 95 United Kingdom 3.3 compare
  21. 95 United States 3.3 compare

See the full ranking of 191 places →

More reference data data for Ghana

All data for Ghana →

Frequently asked questions

What is statin use vs. average non-hdl cholesterol levels in Ghana?
Statin use vs. average non-hdl cholesterol levels in Ghana was 3.3 in 2018, according to World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
What is the highest statin use vs. average non-hdl cholesterol levels recorded in Ghana?
The highest recorded value was 3.3 in 2016.
What is the lowest statin use vs. average non-hdl cholesterol levels recorded in Ghana?
The lowest recorded value was 2.8 in 1980.
How does Ghana rank for statin use vs. average non-hdl cholesterol levels?
Ghana ranks 95th out of 191 countries with data for 2018.
Is statin use vs. average non-hdl cholesterol levels rising or falling in Ghana?
Over the last ten years it is up 6.5%. The long-run trend across the full record is rising.
Where does this Ghana data come from?
The figures come from World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as part of Statin use vs. average non-HDL cholesterol levels. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 39 observations, free to reuse under CC BY 4.0 (Our World in Data).

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.